Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Study will not be started before suitable arrangements are in place
EDITOR The two main reasons behind the high degree of public concern and
debate about the study in Iceland were the initial proposal for an
"opt out" approach to consent for collection of some of the data
and the decision to license the databases exclusively to a commercial
company. Neither of these has ever been considered as a possibility in
the British study. Consent to take part will be on an "opt in"
basis only after full verbal and written explanations and guarantees on
confidentiality. The availability of fully anonymised material to
others in order to pursue the full scientific and therapeutic potential
of the study will be tightly controlled.
The study will be overseen and regulated by a publicly accountable and
independent body responsible for reviewing all its procedures and
activities. In addition, full ethical approval will of course also have
to be obtained. The United Kingdom has well developed, high quality
expertise in both genetics and population based research, and its
diverse population and healthcare system are additional advantages.
Others have emphasised the importance for future health care of
deriving the full benefit from recent and future developments in
genetics.2
While the appropriate regulatory procedures are being put in place
we should not lose sight of the willingness of many people in this
country to take part in research, including work likely to benefit
others perhaps more than themselves. We must ensure that they can
express this readiness through their contribution to important studies
such as the one the Medical Research Council and Wellcome Trust are
setting up.
As chairman of the expert planning group set up by the Medical
Research Council and Wellcome Trust, I can reassure readers of the
article by Kaye and Martin that all the issues they raise about the
proposed population study in the United Kingdom involving genetic
information have been fully recognised.1 The study will
not and cannot be started until arrangements acceptable to all
concerned are in place. These arrangements are currently being actively
developed and entail consultation with lay and professional advisers.
Medical Research Council Epidemiology and Medical Care Unit,
Wolfson Institute of Preventive Medicine, St Bartholomew's and the
Royal London School of Medicine and Dentistry, London EC1M 6BQ
Susan.J.Matthews{at}mds.qmw.ac.uk
| 1. |
Kaye J, Martin P.
Safeguards for research using large scale DNA collections.
BMJ
2000;
321:
1146-1148 |
| 2. |
Fears R, Roberts D, Poste G.
Rational or rationed medicine? The promise of genetics for improved clinical practice.
BMJ
2000;
320:
933-935 |
Educational initiatives are essential for success of population genetic studies
EDITOR This project may well represent the next major advance in clinical
medicine, but several matters arise from the proposal. The active
participation of all the relevant professional groups and the patient
population is a prerequisite for the success of the project, both to
enable the successful recruitment of patients and to maintain the
momentum required to sustain such a long-term study. There are
important educational issues that should be addressed as a matter of
urgency to enable professionals in primary care to recruit patients, to
obtain their informed consent, and to answer questions that arise
during the course of the study.
Current and emerging technologies will allow rapid identification
of mutations causing well described single gene disorders, single
nucleotide polymorphism profiling, and genomic sequencing. These
powerful technologies may enable the identification of predispositions to common, multifactorial disorders and predict individuals' responses to conventional therapeutic interventions. On the basis of discussions with general practitioners and practice nurses, and the findings of a
recent informal survey among general practitioners in South Wales about
attitudes and knowledge of genetics (unpublished data), I think that
few professionals in primary care would be confident in explaining the
nature of these techniques and the importance and implications of the
data that would be generated. This would seriously limit the ability of
professionals in primary care to obtain informed consent and answer
questions that arise over the years of the study. The long term nature
of the proposals reinforces the view that education and training in
genetics, and particularly in the basic science that underpins the
subject, are a priority for medical, nursing, and associated
professions at the basic, specialist, and continuing education stages.
The success of the proposed study and future population genetic studies
are dependent on this educational need being immediately and
effectively addressed.
I was delighted to see the article by Kaye and Martin on the
proposed population health and diversity study of the Medical Research
Council and the Wellcome Trust.1 This proposal involves
the recruitment of around 500 000 patients through primary care for
DNA isolation and genotyping, to be linked to their medical records and
family histories. These will be correlated with the prospective
collection of changes in patients' lifestyles and important health
events over several years.
Clinical and Molecular Genetics Unit, Institute of Child
Health, London WC1N 1EH i.hopkinson{at}ich.ucl.ac.uk
1.
Kaye J, Martin P.
Safeguards for research using large-scale DNA collections.
BMJ
2000;
321:
1146-1148. (4 November.)
© BMJ 2001
What can you learn from this BMJ paper? Read Leanne Tite's Paper+